Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -8.03
- Piotroski Score 4.00
- Grade Buy
- Symbol (LXRX)
- Company Lexicon Pharmaceuticals, Inc.
- Price $1.06
- Changes Percentage (-3.21%)
- Change -$0.04
- Day Low $1.05
- Day High $1.08
- Year High $3.73
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $6.00
- High Stock Price Target $6.00
- Low Stock Price Target $6.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.83
- Trailing P/E Ratio -2.11
- Forward P/E Ratio -2.11
- P/E Growth -2.11
- Net Income $-177,119,000
Income Statement
Quarterly
Annual
Latest News of LXRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025?
An article lists the top multibagger penny stocks of 2025, including Lexicon Pharmaceuticals, analyzing its potential. Multibagger stocks can yield significant returns but are risky. Market trends sug...
By Yahoo! Finance | 2 months ago -
Lexicon Pharmaceuticals (NASDAQ:LXRX) adds US$51m to market cap in the past 7 days, though investors from five years ago are still down 69%
Long term investing can be profitable, but not always immune to losses. For instance, Lexicon Pharmaceuticals' stock has declined significantly over five years, indicating high risk due to low revenue...
By Yahoo! Finance | 5 months ago
